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Phosphoramidon is a potent metalloprotease inhibitor and a widespread tool in cell biology research. It
contains a dipeptide backbone that is uniquely linked to a 6-deoxysugar via a phosphoramidate bridge.
Herein, we report the identification of a gene cluster for the formation of phosphoramidon and its
detailed characterization. In vitro reconstitution of the biosynthesis established TalE as
a phosphoramidate-forming kinase and TalC as the glycosyltransferase which installs the L-rhamnose
moiety by phosphoester linkage.Introduction
Phosphoramidate and phosphonamidate moieties are common
motifs in medicinal chemistry. Nucleoside phosphoramidates
are developed as antiviral prodrugs with great success.1 In
protease inhibitors they serve as peptidomimetics replacing the
carbonyl carbon in the amide bond.2 They can be seen as
transition-state analogues of the enzyme reaction and coordi-
nate to the active site metal ion in metalloproteases.3 In natural
products, however, N–P bonds are comparably rare and little is
known about their biosynthesis.4 Phosphoramidon (Fig. 1; 1)
and its stereoisomer talopeptin (2) have been isolated from
Streptomyces culture broths and are potent inhibitors of met-
alloendopeptidases including thermolysin, Pseudomonas elas-
tase LasB, neutral endopeptidase and endothelin-converting
enzyme.5–7 Phosphoramidon was extensively investigated in
animal models and pilot clinical studies for its effects on
various diseases.8–10 Today, this compound is still a widely used
pharmacological tool in cell biological research. The inhibitory
activity of 1 and 2 has been attributed to the metal-chelating
properties of a phosphoramidate moiety which uniquely links
a deoxysugar to the N-terminus of a L-Leu–L-Trp dipeptide
backbone.11 The deoxysugar consists of L-rhamnose in the casePharmaceutical Institute, University of
il: leonard.kaysser@uni-tuebingen.de
), partner site Tübingen, 72076 Tübingen,
d Infection Medicine Tübingen (IMIT),
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tion (ESI) available. See DOI:
0
of 1 and 6-deoxy-L-talose in the case of 2. The two molecules
belong to a small group of structurally diverse natural products
with N–P bonds (Fig. 1). The biosynthesis of such compounds
has drawn a lot of interest and the biosynthetic gene clusters
(BGCs) were identied for microcin C7 (3) in Escherichia coli,12,13Fig. 1 Selected natural products with phosphoramidate or phospho-
namidate moieties.
This journal is © The Royal Society of Chemistry 2019
Edge Article Chemical Science
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 2
1 
M
ar
ch
 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
0/
29
/2
02
0 
2:
00
:1
9 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Onlineagrocin 84 in Agrobacterium radiobacter,14 fosfazinomycin in
Streptomyces sp. WM6372 15 and phaseolotoxin in Pseudomonas
syringae pv. phaseolicola.16 However, the enzymatic mechanism
for the formation of the N–P bond has so far only been estab-
lished for 3. Here, the adenylating enzyme MccB catalyzes the
formation of the phosphoramidate linkage of a precursor
peptide and AMP via the generation of a succinimide interme-
diate and the consumption of two molecules of ATP.17 Given the
structural difference to 3 and the absence of an adenylyl group
we speculated about a distinct biosynthetic strategy to form the
phosphoramidate bridge in 1 and 2.Results and discussion
Identication of the talopeptin biosynthetic gene cluster
To explore the genetic basis for the assembly of 1 and 2 we
sequenced the genome of Streptomyces mozunensis MK-23, the
original talopeptin producer. This approach resulted in a high
quality dra genome with eight scaffolds and 7708 predicted
genes. Unexpectedly, analysis of the dra genome for the
presence of non-ribosomal peptide synthetase (NRPS) genes
did not result in the identication of a reasonable candidate
pathway. We thus used Cpz31, a rhamnosyltransferase from
the caprazamycin gene cluster,18 as reference to scan the
genome sequence on the assumption, that a homologous
enzyme could be involved in the installation of the deoxysugar
in 2. A BLAST comparison revealed one homolog, TalC, with
45% sequence identity to Cpz31. The respective gene was co-
located with genes for a putative ATP-grasp enzyme (TalD)Fig. 2 Biosynthesis of 1 and 2. (A) Organization of the talose BGC from
S. mozunensis MK-23 and gene cluster table. Genes deleted in the
course of this study are indicated (D). Purple arrows: biosynthetic
genes. Green arrows: transport and regulation. (B) Proposed pathway
for the biosynthesis of 1.
This journal is © The Royal Society of Chemistry 2019and a putative PEP synthase/pyruvate, phosphate dikinase
(TalE; Fig. 2A). Adjacent to this small operon-like structure
were putative genes encoding for transport and regulatory
functions. Based on these ndings a three-reaction pathway to
2 (and 1) would be conceivable (Fig. 2B). TalD would form
a dipeptide (4) from L-Leu and L-Trp. This could serve as
a precursor for TalE to install an N-terminal phosphoramidate
generating 5. The subsequent transfer of the deoxysugar could
be catalyzed by TalC to afford 2.Heterologous expression and gene deletion studies
To conrm the identity of the putative tal gene cluster, we
transferred the pathway on an integrative pCC1FOS derivative
into Streptomyces sp. MK730-62F2 for heterologous expression.
This strain is known to provide activated L-rhamnose for the
endogenous production of caprazamycins and the respective
deoxysugar biosynthesis genes have recently been identied.18,19
To our satisfaction, LC-MS analysis of culture extracts from the
heterologous mutant showed the production of a single new
peak with a mass, retention time and UV-spectrum identical to
a commercial standard of 1 (Fig. 3, S1, S4 and S5†) but with
a 0.2 min shi in retention time to 2. This mass peak was absent
in the culture extracts of the host without the tal cluster. This
nding conrmed that we have found a BGC for the production
of 1 and 2, likely comprising the talCDE operon. It appears that
the deoxysugar transferase TalC is exible towards the stereo-
conguration of the hydroxy group at C-4. To unambiguously
determine the organization and the boundaries of the tal cluster
we individually deleted the genes talC, talD and talE as well as
the bordering regions orf-7 to orf-1 and orf+1 to orf+12 and
expressed themutant clusters heterologously. LC-MS analysis of
culture extracts from the mutant strains showed that the
biosynthesis of 1 was not affected by the Dorf-7–orf-1 and the
Dorf+1–orf+12 deletions. In contrast, the DtalC, DtalD and DtalE
mutations led to an apparent loss of production (Fig. 3). This
strongly indicates that talA, a MerR-like regulatory gene, and
talB, encoding a putative MFS transporter, form the BGC for 1
and 2 together with the talCDE operon. Notably, trace amounts
of 1 could still be detected in cultures of theDtalDmutant byMS
analysis. This might be explained by the supply of 4 from
standard protein degradation processes.Fig. 3 LC-MS analysis of culture extracts for the production of 1 in
Streptomyces sp. MK730-62F2/talMB01 and 2 in S. mozunensis MK-
23. Extracted ion chromatograms (EICs).
Chem. Sci., 2019, 10, 4486–4490 | 4487
Fig. 4 LC-MS analysis of enzyme reactions. Extracted ion chro-
matograms (EICs) for m/z 542 [M  H] (1), m/z 396 [M  H] (5) and

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View Article OnlineATP-grasp enzymes such as TalD activate carboxylic acid
substrates as acylphosphates under consumption of ATP for
subsequent condensation reactions. They have received
increasing attention as discrete amide ligases for their ability to
form peptide bonds in natural product biosynthesis.20 Our
results suggest that the peptide backbone of 1 and 2 is assem-
bled by ATP-grasp biochemistry in analogy to other small-
molecule protease inhibitors e.g. the ketomemicins but in
contrast to the class of hydroxamic acid-containing metal-
loprotease inhibitors which derive from NRPS systems.21–23 To
unambiguously assign the role of TalD in the biosynthesis of 1
and 2 we supplemented cultures of the DtalD mutant with
a synthetic 4 precursor. LC-MS analysis of the culture extracts
showed that the addition of the dipeptide largely restored the
production of 1 in the mutant (Fig. 3). This result conrms the
function of TalD as a dipeptide synthetase in the formation of 1
and 2.m/z 316 [MH] (4). (a) Commercial standard of 1. (b) Enzymatic assay
with TalC (protein extract of DtalE mutant), dTDP-L-rhamnose, TalE, 4
and ATP showed conversion of 4 to 1. (c) Control assay of (b) without
TalC using a protein extract of theDtalCmutant. (d) Control assay of (b)
without dTDP-L-rhamnose. (e) Control assay: protein extract of DtalC
mutant with 4. (f) Control assay: protein extract of DtalEmutant with 4.
(g) Enzymatic assay of TalE with 4 and ATP showed conversion of 4 to
5. (h) Control assay of (g) without TalE. (i) Control assay of (g) without
ATP. (j) Control assay of (g) without 4. Box: observed NMR correlations
of 5.Identication of TalE as an N–P-bond-forming kinase
Next, we wanted to explore the biosynthetic mechanism that
installs the unique deoxysugar phosphoramidate moiety onto
4. Therefore, we cloned the remaining two biosynthetic genes
talC and talE for protein production in E. coli. The putative
kinase His-TalE could be produced in yields of 2.71 mg L1,
whereas His-TalC could not be obtained as soluble protein
under various conditions (Fig. S10 and S11†). TalE has
homology to PEP synthases and pyruvate, phosphate dikinases
(PPDKs). PPDKs catalyze the 2-step conversion of pyruvate,
ATP and phosphate to phosphoenolpyruvate, AMP and PPi in
plants and the reversible reaction bacteria.24 They use a cata-
lytic histidine residue to generate a phosphohistidine inter-
mediate with a high-energy N–P bond that serves as
a phosphate shuttle between the two reaction centers of the
enzyme.25 Phosphohistidine intermediates can be found in
various kinases.26 Some of those enzymes e.g. Hpr or nucleo-
side diphosphate kinases, were shown to transfer the phos-
phoryl group onto histidine residues of other proteins to
regulate their enzymatic activity.27
We thus wondered if TalE might catalyze a similar reaction
using the terminal amine of a dipeptide as the acceptor
substrate instead of a proteinogenic histidine. To test this
hypothesis we incubated puried His-TalE with ATP and
synthetic 4 for 2 hours at 30 C. LC-MS analysis of the reaction
mixture showed the presence of an additional mass peak 5 at
retention time 8.4 min with m/z 396.1 [M – H] (Fig. 4 and S7†).
The production of this new compound was dependent on the
concentration of TalE (Fig. S9†) and absent when one of the
assay components was omitted (Fig. 4). HR-MS measurements
of 5 indicated a molecular formula of C17H23N3O6P (m/zmeas for
[M  H] 396.13400 vs. m/zcalcd for [M  H] 396.13300, D ¼
+2.53 ppm; Fig. S2 and S3†) and thus a possible phosphor-
amidate as the TalE product. To unequivocally determine the
structure of 5 we puried the compound for comparison of the
spectral properties of the product with those of its precursor 4.
Both compounds were subjected to a series of 1H/13C/15N-based
1D/2D NMR standard experiments (Fig. 4 and S12–S27†).4488 | Chem. Sci., 2019, 10, 4486–4490Subsequent analysis of all obtained spectra conrmed the
presence of the Leu–Trp skeleton in 4 and 5. The 1H and 13C
NMR spectrum of 5 was highly similar to the corresponding
spectra of 4, with the exception of the resonances of Leu-a and
Leu-b whose proton resonances shied upeld, while the cor-
responding carbon resonances shied downeld (Tables S1 and
S2†), suggesting already that the phosphorylation had occurred
at the N-terminal leucine residue of 4. This hypothesis was
further corroborated by the interpretation of a 1H decoupled 31P
NMR spectrum, which revealed that 5 contained, in contrast to
4 a phosphorus resonance, whose shi value dP 0.25 was
indicative for a phosphoramidate group (Fig. S28 and S29†).
Final evidence for the existence of a N–P bond in 5 was provided
by a cross-correlation between Leu-a and P, observed in the
1H–31P HMBC NMR spectrum of 5 (Fig. 4, S30†). A comple-
mentary MS/MS analysis of 5 of the [M + H]+ ion at m/z 398
produced b- and y-series fragment ions that were also in full
agreement with the proposed structure (Fig. S8†).
These results conrm that TalE catalyzes the second step in
the biosynthesis of 1 and 2 using the TalD product 4 and ATP as
substrates to form 5. To the best of our knowledge, TalE
represents the rst enzyme in natural product biosynthesis that
generates a small molecule phosphoramidate by simple phos-
phorylation of an amine. Very recently, Raushel and co-workers
reported on a so far unprecedented enzyme-catalyzed phos-
phorylation of an amide to generate g-phospho-L-glutamine.28,29
The respective enzyme, Cj1418, is involved in O-methyl phos-
phoramidate modication of capsular polysaccharides in
Campylobacter jejuni. Notably, Cj1418 shows conserved proteinThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinedomains typical for PEP synthases and PPDKs but has no
signicant sequence similarity to TalE (<20% on AA level). It
appears that members of this family of kinase enzymes have
evolved separately in bacteria to synthesize small-molecule
phosphoramidates in the primary and secondary metabolism.
It is tempting to speculate that putative PPDK homologs enco-
ded in the BGCs for agrocin 84 and phaseolotoxin might have
an analogous role in the respective pathways.14,16In vitro biosynthesis of phosphoramidon
We next aimed to establish 5 as a genuine intermediate in the
biosynthesis of 1. Therefore, we added dTDP-L-rhamnose and
a TalC-containing protein extract to the TalE assay. Aer incu-
bation for 16 h at 30 C we analyzed the reaction mixture by LC-
MS and identied a single product peak matching 1 in retention
time, UV spectrum, mass and MS/MS fragmentation (Fig. 4, S1,
S6 and 7†). 1was not produced when either 5, dTDP-L-rhamnose
or TalC were absent in the assay. These results show that TalC
uses 5 as an acceptor substrate to catalyze the transfer of
a deoxysugar to the phosphoryl group. In general, glycosylation
is a common theme in natural product biosynthesis altering
target specicity and pharmacological properties of a parent
scaffold.30 Particularly, 6-deoxyhexoses are prevalent features in
bacterial secondary metabolites. The substrate promiscuity of
the respective glycosyltransferases has been extensively used to
engineer the structure of bioactive small-molecules.31 In most
cases these enzymes build a direct O-glycosidic link to the
aglycon although the formation of thioglycosides, N-glycosides
and C-glycosides is also known.32–34 Attachment of sugars in
natural product biosynthesis via phosphoester linkage,
however, is very rare and has only been functionally investigated
for moenomycins. Here, Walker and co-workers showed that
MoeGT1 transfers galacturonic acid from UDP-GalUA to a far-
nesyl phosphoglycerate precursor.35 The enzymatic installation
of an L-rhamnose moiety to the phosporamidate of 5 thus
represents a so far undescribed reaction in natural product
biochemistry and adds TalE as a unique biocatalyst to the
family of 6-deoxysugar transferases.Conclusions
In conclusion, we have identied the gene cluster for the
biosynthesis of phosphoramidate metalloprotease inhibitors.
Chemical complementation and in vitro reconstitution revealed
a three-reaction pathway to form 1 and 2, which involves
exceptional biochemistry. An ATP-grasp amide ligase, a phos-
phoryl transferase and a deoxysugar transferase work together
in the condensation of two amino acids and the subsequent
linkage of a 6-deoxyhexose to the resulting dipeptide via
a phosporamidate bridge. A preliminary search in public
genome databases found a number of homologous orphan
pathways containing a talCDE-like putative operon (Fig. S31†).
Given the possibility that the encoded ATP-grasp enzymes and
glycosyltransferases may express a different substrate tolerance
than TalD and TalC, respectively, the identied gene clusters
could direct the synthesis of new metalloprotease inhibitors.This journal is © The Royal Society of Chemistry 2019Additionally, both enzymes have potential as exible bio-
catalysts for in vivo and in vitro engineering of bioactive small-
molecules.
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